How to read hormone tests results

ESTROGENS

Estrone (E1), estriol (E3), and estradiol (E2) represent the primary endogenous estrogens, with E1typically being the predominant form detected in urine, followed by E3 and then E2. A reduced ratio of E3 to the combined concentration of E1 and E2 [E3/(E1 + E2)] may reflect a relative excess of the more proliferative estrogens (E1 and E2) compared to the less potent E3, and has been associated with an elevated risk of estrogen-sensitive malignancies such as breast cancer.

Optimal Phase I estrogen metabolism is characterised by preferential hydroxylation at the C-2 position, resulting in higher urinary concentrations of 2-hydroxyestradiol (2-OH E2) and 2-hydroxyestrone (2-OH E1) relative to the 4-hydroxylated metabolites (4-OH E2 and 4-OH E1). Elevated levels of 4-hydroxylated estrogens have been implicated in increased oxidative stress and genotoxicity and are associated with a higher risk of estrogen-related carcinogenesis, including breast cancer. Additionally, a lower 2-hydroxylation to 16α-hydroxylation ratio [2-OH(E1+ E2)/16α-OH E1] has been correlated with increased breast cancer risk in premenopausal women, whereas in postmenopausal women, a higher proportion of 16α-OH E1 may exert a protective effect due to its weaker estrogen receptor affinity and activity.

Phase II estrogen metabolism involves methylation of catechol estrogens, primarily via catechol- O-methyltransferase (COMT). This process converts the 2-hydroxylated estrogens into 2- methoxyestrone (2-MeO E1) and 2-methoxyestradiol (2-MeO E2), which exhibit anti-proliferative and anti-angiogenic properties, thereby reducing oncogenic potential. Similarly, methylation of 4-hydroxylated estrogens to 4-methoxyestrone (4-MeO E1) and 4-methoxyestradiol (4-MeO E2) is critical for the detoxi cation of these genotoxic intermediates. Reduced ratios of methylated to hydroxylated estrogens—specifically 2-MeO E1/2-OH E1, 4-MeO E1/4-OH E1, and 4-MeO E2/4-OH E2—may reflect impaired COMT activity or methyl donor deficiency, both of which have been associated with increased estrogen-related cancer risk, particularly breast cancer.

High levels indicate excessive exposure to this environmental endocrine disruptor. Refer to detailed comments and treatment guidelines.

PROGESTOGENS

Pregnanediol (Pgdiol), the principal urinary metabolite of progesterone, serves as a marker of endogenous progesterone production. It is typically unaffected by transdermal progesterone application. A low Pgdiol/E2 ratio may indicate relative estrogen dominance.

Allopregnanolone and allopregnanediol are 5α-reduced pregnane metabolites of progesterone, with neuroactive properties that promote anxiolytic and sedative effects. These metabolites often rise with oral progesterone therapy. In contrast, the pregnene metabolites 3α- and 20α- dihydroprogesterone exhibit antiproliferative ef Allopregnanediol fects, including tumor-inhibitory activity in breast tissue. A low pregnane-to-pregnene ratio may re ect reduced 5α-reductase activity.

Deoxycorticosterone (DOC) and corticosterone are precursors in the mineralocorticoid pathway leading to aldosterone synthesis, which regulates sodium retention, water balance, and blood pressure. Although DOC is a weak mineralocorticoid, elevated levels may contribute to fluid retention and hypertension.

ANDROGENS

Dehydroepiandrosterone (DHEA) and androstenedione serve as androgen precursors, primarily from the adrenal glands and ovaries, respectively. Low DHEA may indicate reduced adrenal output or increased peripheral conversion to active sex steroids. Testosterone (T) and epitestosterone (Epi-T) are normally produced in a 1:1 ratio; a high T/Epi-T ratio may suggest exogenous testosterone use. Dihydrotestosterone (DHT), formed via 5α-reductase, contributes to androgenic symptoms (e.g. acne, alopecia, hirsutism) and may increase prostate cancer risk when estrogen is elevated. The neurosteroid 5α,3α-androstanediol supports dopaminergic tone and mood. Elevated aromatase activity promotes excess T-to-E2 conversion, limiting DHT synthesis and potentially increasing estrogen-driven cancer risk.

TO LEARN MORE: https://go.hotmart.com/V103706333T